Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.

Janssen, Quisette P; O'Reilly, Eileen M; van Eijck, Casper H J; Groot Koerkamp, Bas

Janssen, Quisette P; O'Reilly, Eileen M; van Eijck, Casper H J; Groot Koerkamp, Bas.

Afiliação

Janssen QP; Department of Surgery, Erasmus MC University Medical Center, Rotterdam, Netherlands.
O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
van Eijck CHJ; David M. Rubenstein Center for Pancreatic Cancer Research, New York, NY, United States.
Groot Koerkamp B; Department of Surgery, Erasmus MC University Medical Center, Rotterdam, Netherlands.

Front Oncol ; 10: 41, 2020.

Article em En | MEDLINE | ID: mdl-32083002

Palavras-chave

FOLFIRINOX; borderline resectable; evidence; neoadjuvant; ongoing trials; pancreatic cancer; pancreatic ductal adenocarcinoma; resectable

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Systematic_reviews Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google